Georgia's Online Cancer Information Center

Find A Treatment Site

Northside Hospital Cancer Institute

Northside Hospital Cancer Institute
Atlanta, Georgia

Northside Hospital Cancer Institute offers the best of both worlds: clinical excellence on par with academic-based programs, along with the personalized and attentive care typically associated with a community hospital. Northside, which has been offering cancer care services since 1978, is one of the largest and most respected providers of cancer care services in the Southeast.

 
  • The Blood & Marrow Transplant Program at Northside Hospital has ranked #1 in the United States for the third consecutive year, for having the best survival rates for matched related and unrelated donors (MUD) /allogeneic transplants.
  • More cases of breast cancer and gynecologic (cervical, ovarian and uterine) cancer are diagnosed and treated than at any other hospital in the Southeast.
  • More prostate cancer treatments are performed at Northside than at any other hospital in Atlanta
  • Fully accredited by the American College of Surgeons Commission on Cancer.
    Northside also received an Outstanding Achievement Award.

Our renowned program also consists of palliative care, cancer genetics, screenings, research, support and survivorship.

(404) 851-8000
www.northside.com

Treatment Sites in Georgia

Clinical Trials in Georgia

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Cancer Type: Lung Cancer

A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma, Unknown Primary

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Cancer Type: Breast Cancer

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Cancer Type: Unknown Primary, Uterine Cancer

A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type: Ovarian Cancer

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Cancer Type: Liver Cancer / Hepatoblastoma

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type: Non-Hodgkin Lymphoma

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type: Solid Tumor

CIBMTR Research Database
Cancer Type: Hematopoietic Malignancies, Solid Tumor
Study Coordinator: Stacey Brown - 404-780-7965


Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type: Leukemia

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Cancer Type: Lung Cancer

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer, Unknown Primary
Study Coordinator: - 404-303-3355


IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Cancer Type: Melanoma

International CIPN Assessment and Validation Study (ICAVS)
Cancer Type: Unspecified

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type: Melanoma

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Cancer Type: Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Cancer Type: Leukemia

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer Type: Breast Cancer, Unknown Primary

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor

Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type: Lung Cancer

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor
Study Coordinator: - 404-303-3355


Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Cancer Type: Breast Cancer

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer, Unknown Primary

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
Cancer Type: Leukemia

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Cancer Type: Unknown Primary

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
Cancer Type: Breast Cancer

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Cancer Type: Colon/Rectal Cancer, Unknown Primary

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Cancer Type: Lung Cancer

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer, Unknown Primary

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Breast Cancer, Unknown Primary

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
Study Coordinator: - 404-303-3355


Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Cancer Type: Melanoma

Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Cancer Type: Colon/Rectal Cancer, Unknown Primary
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.